Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline (GSK) is developing with US partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.
WATCH MORE: https://thestartv.com/c/news
SUBSCRIBE: https://cutt.ly/TheStar
LIKE: https://fb.com/TheStarOnline